Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02042183
Other study ID # SAG/0211PFC-1131
Secondary ID 2013-004384-31EM
Status Completed
Phase Phase 3
First received
Last updated
Start date December 13, 2013
Est. completion date July 27, 2016

Study information

Verified date July 2020
Source Mallinckrodt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.


Description:

Dose administration details:

- Participants with a body weight <50 kg at baseline received Lubiprostone 12 mcg BID for 12 weeks. If the dose was safe but did not show any efficacy at Week 1, dosage was increased to 24 mcg BID.

- Participants with a body weight >50 kg at baseline received Lubiprostone 24 mcg BID for 12 weeks. If the dose was unsafe at Week 1, dosage was decreased to 12 mcg BID.


Recruitment information / eligibility

Status Completed
Enrollment 606
Est. completion date July 27, 2016
Est. primary completion date July 27, 2016
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria:

- Medically-confirmed diagnosis of Functional Constipation per Rome III Diagnostic Criteria for Childhood Functional Constipation

- At least 6 years of age but less than 18 years of age at the time of randomisation

- Only stable dose of selective serotonin re-uptake inhibitors (SSRIs), serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors are allowed if subject is taking antidepressants

Exclusion Criteria:

- Any gastrointestinal (GI) condition, other than constipation and/or irritable bowel syndrome (IBS), affecting GI motility or defecation

- Untreated faecal impaction at the time of screening

- Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lubiprostone
12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
Placebo
0 mcg soft capsules of placebo for oral administration

Locations

Country Name City State
Belgium Universitair Kinderziekenhuis Brussel Brussel
Belgium University Hospital Gasthuisberg Leuven
Belgium CHC - Clinique Saint-Joseph Montegnee
Canada London Health Sciences Centre London Ontario
Canada Sainte Justine University Health Center Montreal
Canada Centre de recherche du CHUS Sherbrooke Quebec
France CHU-Bordeaux Bordeaux
France Groupe Hospitalier Est Bron
France Armand-Trousseau Teaching Hospital Paris
France Hôpital Necker Paris-Cedex
Netherlands Emma Children's Hospital Amsterdam
Netherlands Amphia Ziekenhuis Breda
Netherlands Maasstad Hospital Rotterdam Rotterdam
Netherlands Isala Klinieken Zwolle
Poland Medical University of Bialystok Bialystok
Poland Szpital Uniwersytecki Bydgoszcz
Poland ATOPIA Poradnie Specjalistyczne Krakow
Poland Medical University of Lodz Lodz
Poland Szpital Pediatryczny ICZMP Lodz
Poland Gabinet Lekarski Bartosc Korczowski Rzeszow
Poland Children's Memorial Health Institute Warszaw
Poland Children's Memorial Health Institute Warszaw
Poland Przychodnia Specjalistyczna PROSEN Warszawa
United Kingdom Kent and Canterbury Hospital Canterbury
United Kingdom Darlington Memorial Hospital Darlington
United Kingdom Royal Hospital for Sick Children Glasgow
United Kingdom Chelsea and Westminster Hospital NHS Foundation Trust London
United Kingdom Great Ormond Street Hospital for children NHS Foundation Trust London
United Kingdom Royal London Hospital London
United Kingdom Sheffield Children Hospital Sheffield
United States Texas Tech University Health Sciences Center Amarillo Texas
United States Children's Center for Digestive Healthcare/GI Care for Kids Atlanta Georgia
United States Austin Center for Clinical Research Austin Texas
United States Johns Hopkins Children's Center Baltimore Maryland
United States A1 Clinical Research Baytown Texas
United States PriMed Clinical Research Beavercreek Ohio
United States Northwest Clinicial Research Center Bellevue Washington
United States Pioneer Clinical Research Bellevue Nebraska
United States University of Alabama Pediatric Gastroenterology Birmingham Alabama
United States Boston Children's Hospital Boston Massachusetts
United States Digestive Diseases and Nutrition Center Women and Childrens Hospital of Buffalo Buffalo New York
United States University of Vermont Medical Center Burlington Vermont
United States UNC School of Medicine Chapel Hill North Carolina
United States Coastal Clinical Research Charleston South Carolina
United States Coastal Pediatric Associates - James Island Charleston South Carolina
United States Pediatric Research of Charlottesville, LLC Charlottesville Virginia
United States MCB Clinical Research Colorado Springs Colorado
United States Nationwide Children's Hospital Columbus Ohio
United States 3rd Coast Research Associates Corpus Christi Texas
United States WCCT Global Costa Mesa California
United States Childrens Medical Center Dallas Dallas Texas
United States UnityPoint Health Des Moines/ Blank Children's Clinic Des Moines Iowa
United States Square-1 Clinical Research, Inc. Erie Pennsylvania
United States INOVA Pediatric Digestive Diseases Center Fairfax Virginia
United States Northwest Arkansas Pediatric Clinic Fayetteville Arkansas
United States Cook Children's Medical Center Fort Worth Texas
United States University of Florida Gainesville Florida
United States Greenville Health System Greenville South Carolina
United States Cyn3rgy Research Gresham Oregon
United States Palmetto Professional Research Hialeah Florida
United States Baylor College of Medicine Houston Texas
United States University of Iowa Children's Hospital Iowa City Iowa
United States Gastrointestinal Associates, PA Jackson Mississippi
United States The Jackson Clinic, P.C. Jackson Tennessee
United States University of Mississippi Medical Center Jackson Mississippi
United States Smart Medical Research, Inc. Jackson Heights New York
United States Nemours Children's Clinic Jacksonville Florida
United States The Children's Mercy Hospital Kansas City Missouri
United States Envision Clinical Research, LLC Laredo Texas
United States Midwest Children's Health Research Institute Lincoln Nebraska
United States Applied Clinical Research of Arkansas Little Rock Arkansas
United States Arkansas Children's Hospital Research Institute Little Rock Arkansas
United States Bridgerland Clinical Research Logan Utah
United States Loma Linda University Health Care Loma Linda California
United States DCOL Center for Clinical Research Longview Texas
United States Children's Hospital Los Angeles Los Angeles California
United States University of Louisville Research Foundation Inc. Kosair Charities Pediatric Clinical Research Unit Louisville Kentucky
United States Le Bonheur Children's Hospital Memphis Tennessee
United States Acevedo Clinical Research Associates Miami Florida
United States Savin Medical Group Research Center Miami Lakes Florida
United States Medical College of Wisconsin Milwaukee Wisconsin
United States University of South Alabama Women's and Children's Hospital Mobile Alabama
United States Coastal Pediatrics Associates - Mount Pleasant Mount Pleasant South Carolina
United States Monroe Carell Junior Children's Hospital at Vanderbilt Nashville Tennessee
United States Children's Hospital New Orleans Louisiana
United States Morgan Stanley Children's Hospital of New York Presbyterian New York New York
United States NY Presbyterian Weill Cornell New York New York
United States PediaResearch, LLC - Newburgh Newburgh Indiana
United States The Children's Hospital of the King's Daughter Norfolk Virginia
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Children's Hospital of Orange County Orange California
United States Digestive & Liver Center of Florida Orlando Florida
United States PediaResearch, LLC - Owensboro Owensboro Kentucky
United States Center For Children's Digestive Health Park Ridge Illinois
United States Nemours Childrens Clinic Pensacola Florida
United States Methodist Medical Center Peoria Illinois
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States St. Christopher's Hospital for Children/Drexel University Philadelphia Pennsylvania
United States Arizona Children's Center at Maricopa Medical Center Phoenix Arizona
United States Phoenix Children's Hospital Phoenix Arizona
United States Children's Hospital of Pittsburgh UPMC Pittsburgh Pennsylvania
United States Zain Research LLC Richland Washington
United States Pediatric Gastroenterology Carilion Medical Center Roanoke Virginia
United States Mayo Clinic Rochester Minnesota
United States Primary Children's Medical Center Salt Lake City Utah
United States University of California, San Francisco San Francisco California
United States Medical Clinics of Sealy Sealy Texas
United States Willis-Knighton Physician Network Shreveport Louisiana
United States Virgo-Carter Pediatrics Silver Spring Maryland
United States Spartanburg Medical Research Spartanburg South Carolina
United States Wee Care Pediatrics Syracuse Utah
United States MultiCare Health System Institute for Research and Innovation Tacoma Washington
United States Toledo Children's Hospital Toledo Ohio
United States AAPRI Clinical Research Warwick Rhode Island
United States Emmerson Clinical Research Washington District of Columbia
United States Heartland Research Associates Wichita Kansas
United States Nemours/Alfred I. duPont Hospital for Children Wilmington Delaware

Sponsors (2)

Lead Sponsor Collaborator
Sucampo Pharma Americas, LLC Sucampo AG

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  France,  Netherlands,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Classified as Overall Responders at Week 12 An overall responder is defined as a participant who qualified as a weekly responder for 9 of the 12 treatment weeks, with durability demonstrated by at least 3 of the responder weeks occurring during the last 4 weeks of the treatment period. A weekly responder is defined as a participant who has at least 3 spontaneous bowel movements during the week, and at least one more than at baseline. at Week 12
Secondary Mean Number of SBMs Observed Each Week for 12 Weeks Data provided is based on observed cases. Baseline is the average of the 2 weeks before being randomized. Participants are summarized by actual dose received after week 1. within 12 Weeks
See also
  Status Clinical Trial Phase
Completed NCT05032534 - Examination of a New Irrigation System for Transanal Irrigation in Children With Fecal Incontinence N/A
Completed NCT04587635 - Evaluation of Changes in Bowel Movement Frequency Following the Consumption of PHGG in Adults With Constipation N/A
Completed NCT03821532 - Adherence/Outcomes After Use of Constipation Action Plan N/A
Recruiting NCT06122558 - Efficacy of Probiotic Against Functional Constipation Phase 2
Recruiting NCT04086134 - Physiological, Microbiological and Metabolomic Effects of Fruit Products N/A
Recruiting NCT01587846 - Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children Phase 3
Recruiting NCT05496543 - Acupuncture for Functional Constipation in Older Adults N/A
Completed NCT05447481 - Evaluation of the Effect of Chicory Inulin-type Fructans in Constipated Adults N/A
Completed NCT05035784 - RCE With FMT in the Treatment of Childhood Constipation N/A
Recruiting NCT06221722 - Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
Suspended NCT04306939 - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Recruiting NCT05823259 - The Impact of Respiratory Muscle Training and Patient Education on Chronic Constipation Outcomes N/A
Not yet recruiting NCT06438068 - Influence of Modern Colon Hydrotherapy on Intestinal Transit N/A
Withdrawn NCT05321953 - The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation N/A
Active, not recruiting NCT05363553 - Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study N/A
Recruiting NCT06031025 - Prevalence and Natural History of Functional Gastrointestinal Disorders Among At-risk Infants.
Recruiting NCT05432453 - The Relationship Between Functional Constipation and Sacroiliac Joint Dysfunction
Not yet recruiting NCT05191810 - Efficacy of Educational Intervention as Supporting Element in the Treatment of Functional Constipation in Children N/A
Not yet recruiting NCT06100055 - The ReVo Study: Low-volume vs High-volume Rectal Irrigation N/A
Recruiting NCT04148248 - A Pilot Study to Explore the Role of Gut Flora in Chronic Constipation